Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 Dosing of patients in Part A open-label extension (OLE) ongoing Cash and cash equivalents of $49.0 million as of September 30, 2025 expected to provide financial runway into 2027 WALTHAM, Mass. , Nov. 13, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB)... Read More

SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc . (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has completed enrollment in Part B of its... Read More

WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m. E.T. on Thursday , September 4 th at the 2025 Wells Fargo Healthcare Conference. A webcast of the... Read More

Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 Strengthened leadership team with appointment of Adrien Sipos , M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer Cash and cash equivalents of $54.8 million as of June 30, 2025 , which is now expected to... Read More

Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience WALTHAM, Mass. , June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today... Read More

First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 First patient dosed in SIGNAL-AA Part A open-label extension (OLE) Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting Cash and cash equivalents of $65.5... Read More

WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA.... Read More

SIGNAL-AA Part B topline data readout on-track for 1H'26 WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and... Read More

Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part B on track to dose patients in 1H'25;... Read More

Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound... Read More

Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) WALTHAM, Mass. , Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that... Read More

WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Date: Wednesday, March 5, 2025 Presentation Time: 11:50 a.m. E.T. Location: Boston, MA... Read More

Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 Company to discontinue renal basket trial for ADX-097 to conserve resources and evaluate strategic options for its... Read More

WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a virtual company presentation at 4:00 p.m. E.T. on Tuesday, February 11, 2025 at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. A webcast of the... Read More

SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet primary endpoint in Part B Across both trials, bempikibart was observed to be safe and well tolerated;... Read More

Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials expected in December Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated renal diseases, with topline data expected in 2H'25 and initial open-label data in 1H'25 Cash and cash equivalents of $89.1 million as of September 30, 2024 expected to provide... Read More

WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc . (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA. A webcast of the presentation will... Read More

Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 WALTHAM, Mass. , Oct. 14, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,... Read More

WALTHAM, Mass. , Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Location: New York, NY 2024 Cantor... Read More

Exceeded enrollment target due to patient demand; trial size increased to 121 patients Bempikibart topline results remain on track to be released in Q4'24 WALTHAM, Mass. , July 9, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it has completed enrollment in the SIGNAL-AD Phase... Read More

WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024 . "We are pleased... Read More

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date for such distribution is... Read More

Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notification ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the... Read More

The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and... Read More

Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates. Homology recently shared a summary of safety and efficacy data on the first dose cohort of the pheEDIT... Read More

Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU Evaluating Strategic Options for the Company and Pipeline of Genetic Medicines, including HMI-10 3 BEDFORD, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent... Read More

Announced Today Encouraging Initial Clinical Data from First Dose Level of pheEDIT Trial Evaluating HMI-103 BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value. Earlier today, Homology... Read More

Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (<360 μmol/L) * ; At 31 Weeks Post-Dose, Phe Level 319 μmol/L With a 59% Reduction from Baseline, Even After Dietary Protein Supplementation Participant 2 Plasma Phe Level Reduction of 49% Change from Baseline at 17 Weeks Post-Dose HMI-103 Has Been Generally... Read More

New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs in the Future Presented Methods to Accelerate Identification of Genomic Sites that Result in Improved Homologous Recombination-Based Gene Editing Efficiency BEDFORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company,... Read More

On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and Potential for Re-Dosing with AAVHSCs, at Upcoming ASGCT Meeting Solid Financial Position with Anticipated Cash Runway into Fourth Quarter 2024 BEDFORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a... Read More

First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal... Read More

BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene editing trial for phenylketonuria (PKU) and the Phase 1 juMPStart gene therapy trial for Hunter syndrome (MPS II). Additionally,... Read More

On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome Anticipated in Second Half of 2023; Trial Recruiting in the U.S. and Canada Anticipated Cash Runway Into Fourth Quarter 2024 Enables Execution Against Key Milestones BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology... Read More

BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development and Operations, at Homology, and she has been instrumental in advancing Homology’s gene editing and gene therapy clinical... Read More

BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology’s website... Read More

Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for MLD Showed Robust CNS Distribution and Expression with Improved Packaging Productivity BEDFORD, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the... Read More

Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism of Action Demonstrated Significantly Increased Potency in PKU Model BEDFORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today... Read More